TG Therapeutics
TGTX
79 hedge funds and large institutions have $332M invested in TG Therapeutics in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 10 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 18
71% more call options, than puts
Call options by funds: $5.45M | Put options by funds: $3.19M
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
12% more capital invested
Capital invested by funds: $296M → $332M (+$36.3M)
5% more funds holding
Funds holding: 75 → 79 (+4)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$19.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.2M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.6M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$4.92M |
| 5 |
BM
Bridger Management
New York
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$12.6M |
| 2 |
HH
HWG Holdings
Houston,
Texas
|
-$3.89M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.41M |
| 4 |
Barclays
London,
United Kingdom
|
-$2.69M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$2.45M |
TGTX Hedge Fund Activity: Q1 2015 in Review
79 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2015, worth a combined $332M — up 12% from $296M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TGTX positions and 10 closed out — a net gain of 4 holders — while 40 added to existing stakes and 18 trimmed.
The largest buyer was State Street, adding an estimated $19.9M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $12.6M sold.
- 79 institutional investors held TG Therapeutics (TGTX) as of Q1 2015, up from 75 in Q4 2014.
- Funds reported $332M of TG Therapeutics stock for Q1 2015, up 12% quarter-over-quarter.
- 14 funds opened new TG Therapeutics positions in Q1 2015 and 10 closed out, a net change of +4 holders.
- The largest TG Therapeutics buyer in Q1 2015 was State Street, an estimated $19.9M added.
- The largest TG Therapeutics seller in Q1 2015 was JP Morgan Chase, an estimated $12.6M sold.
Based on aggregated 13F filings for Q1 2015.